{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:23:00Z","timestamp":1767864180153,"version":"3.49.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.2217\/imt-2022-0166","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T08:35:30Z","timestamp":1676450130000},"page":"267-281","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Real-world Maintenance Therapy and Survival Outcomes For Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-7633","authenticated-orcid":false,"given":"Himani","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Center for Observational & Real-World Evidence, Merck & Co Inc, Rahway, NJ07065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KayOnda","family":"Bayo","sequence":"additional","affiliation":[{"name":"College of Population Health, Thomas Jefferson University, Philadelphia, PA19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8046-5016","authenticated-orcid":false,"given":"Yimei","family":"Han","sequence":"additional","affiliation":[{"name":"Real World Advanced Analysis, Eli Lilly & Company, Indianapolis, IN46285, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-3571","authenticated-orcid":false,"given":"Catherine Elizabeth","family":"Muehlenbein","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Eli Lilly & Company, Indianapolis, IN46285, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun Emily","family":"Zhu","sequence":"additional","affiliation":[{"name":"Medical Affairs\/Real World Evidence Biostatistics, Myovant Sciences, Brisbane, CA94005, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Clinical Development, Oncology, Gilead Sciences, Foster City, CA94404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"National Comprehensive Cancer Network\n. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae ) for non-small-cell Lung Cancer V.1. MS-79 (2023)."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"issue":"7","key":"e_1_3_5_6_1","first-page":"S448","article-title":"KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC","volume":"33","author":"Garassino MC","year":"2022","unstructured":"Garassino MC , GadgeelS , SperanzaGet al. KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC. Ann. Oncol.33(Suppl. 7), S448\u2013S554 (2022).","journal-title":"Ann. Oncol."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.015"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.004"},{"issue":"2","key":"e_1_3_5_9_1","first-page":"105","article-title":"Maintenance therapy in non-small-cell lung cancer","volume":"1","author":"Schmid-Bindert G","year":"2012","unstructured":"Schmid-Bindert G . Maintenance therapy in non-small-cell lung cancer. Transl Lung Cancer Res1(2), 105\u2013110 (2012).","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.980765"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0353"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88453-8"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02340-0"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7205"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.021"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.5_suppl.50"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.911026"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.5301\/JBM.2012.9314"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999343"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100397"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0177"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.08.003"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"e_1_3_5_25_1","unstructured":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With non-small-cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091\/KEYNOTE-091) (PEARLS). www.clinicaltrials.gov\/ct2\/show\/NCT02504372 (November 28)."},{"key":"e_1_3_5_26_1","unstructured":"DA approves atezolizumab as adjuvant treatment for non-small-cell lung cancer. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer (November 28)."},{"key":"e_1_3_5_27_1","unstructured":"FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small-cell lung cancer. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung (November 28)."},{"key":"e_1_3_5_28_1","unstructured":"A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in non-small-cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1 L or 2 L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02864251 (January 11)."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00382-5"},{"key":"e_1_3_5_30_1","unstructured":"Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous non-small-cell Lung Cancer (NSCLC) (MK-3475-789\/KEYNOTE-789). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03515837 (January 11)."},{"key":"e_1_3_5_31_1","unstructured":"A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04460456 (November 28)."},{"key":"e_1_3_5_32_1","unstructured":"Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous non-small-cell Lung Cancer (A Lung-MAP Treatment Trial). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04625647 (November 28)."},{"key":"e_1_3_5_33_1","unstructured":"Subcutaneous Atezolizumab Non-Inferior to IV Formulation in Locally Advanced or Metastatic NSCLC. www.targetedonc.com\/view\/subcutaneous-atezolizumab-non-inferior-to-iv-formulation-in-locally-advanced-or-metastatic-nsclc (November 28)."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-140"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02446"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2022-0166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:56:11Z","timestamp":1715946971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2022-0166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.2217\/imt-2022-0166"],"URL":"https:\/\/doi.org\/10.2217\/imt-2022-0166","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}